Current issues in epidemiology and prevention of pneumonia associated with artificial lung ventilation

From 2016 to the present, hospital-acquired pneumonia has been the leading cause of healthcare-associated infections in the Russian Federation. Pneumonia associated with artificial lung ventilation is an independent risk factor for mortality, and the costs associated with its treatment range from $ 9,966 to EUR 20,965. A generalized strategy for the prevention of pneumonia associated with artificial lung ventilation is presented, which includes: ensuring the safety of the hospital environment, ensuring the safety of patient medical technologies, early detection of patients with signs of infectious diseases, and training of medical personnel. It is necessary to consolidate specialists from various fields to systematize best practices and develop guidelines at the national and regional levels.